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TO THE EDITOR
Acute generalized exanthematous pus-
tulosis (AGEP) is a severe cutaneous
drug reaction (Sidoroff et al., 2007)
occurring in one to five individuals per
million per year (Sidoroff et al., 2001). It
is characterized by widespread sheets
of sterile, nonfollicular, pinhead-sized
pustules arising on edematous
erythema with a tendency to involve
major flexures, and systemic symptoms
(Sidoroff et al., 2001; Pirmohamed et al.,
2011). The immunogenetic patho-
physiology of AGEP has remained
largely unclear, although in a single
case an HLA-A*31:01 association was
observed (McCormack et al., 2011).
AGEP shares clinical (Whittam et al.,
2000), histological (Halevy et al., 2010),
and immunological (Halevy, 2009)
features with generalized pustular
psoriasis (GPP). In GPP, we and others
have recently identified recessive
mutations in the IL36RN gene, which
encodes the anti-inflammatory IL-36-
receptor antagonist, IL-36Ra. IL-36Ra
blocks the pro-inflammatory cytokines
IL-36a, IL-36b, and IL-36g. When
IL36RN is mutated, IL-36 signaling is
uncontrolled and enhanced production
of IL-6, IL-8, IL-1a, and IL-1b occurs
(Onoufriadis et al., 2011), which
might give rise to pustular eruptions in
GPP. Given the phenotypic parallels
between GPP and AGEP, this
study addresses the hypothesis that
IL36RN missense mutations may also
underlie some forms of AGEP.
RegiSCAR (International Registry of
Severe Cutaneous Adverse Reactions
with collection of biological samples),
which started in 2003, is an ongoing
pharmaco-epidemiologic, ethically and
institutionally approved study that
adheres to the declaration of
Helsinki principles, with collection of
biological samples on severe cutaneous
adverse reactions including AGEP.
Following written consent, a reaction-
specific, standardized questionnaire
is completed on any patients admitted
to a contributing hospital with the
suspicion of having AGEP. A
committee blinded for drugs and other
exposures reviews clinical data,
histopathology, and photographs of
each potential case of AGEP, and
validates the diagnosis according to a
standardized process (Supplementary
Figure S1 online) using a published
score (Supplementary Table S1 online;
Sidoroff et al., 2001). RegiSCAR
provided 96 cases for inclusion, all of
which fulfilled the criteria for probable
(n¼ 50) or definite (n¼ 46) cases. The
clinical features are summarized in
Table 1. DNA was extracted from
venous blood. All coding regions and
associated splice sites of the IL36RN
locus, as well as 1,000 bp of putative
promoter region, were amplified by PCR
(Supplementary Table S2 online) and
Sanger-sequencing was performed for
all 96 patients. Within the cohort of 96
confirmed AGEP cases, a French patient
of Tunisian ancestry was homozygous
for a previously described loss-of-
function mutation (c.80T4C, p.Leu27-
Pro) in IL36RN (Marrakchi et al., 2011;
Supplementary Figures S2 and S3
online). In addition, three patients were
demonstrated to have heterozygous
mutations, namely, two Germans
(c.338C4T, p.Ser113Leu) and one Rus-
sian included in Germany (c.142C4T,
p.Arg48Trp). All these mutations
had been previously identified either
as homozygous (Marrakchi et al.,
2011) or compound heterozygous
in GPP (Onoufriadis et al., 2011).
Amplification of the entire IL36RN
locus in the three heterozygous
patients generated a single PCR
product of the expected molecular
weight (3.5 kb, data not shown). This
excludes the possibility that these
individuals may carry large intragenic
deletions, alongside single-nucleotide
substitutions identified by direct
sequencing. The frequency of the
damaging heterozygous alleles was
compared with 4,300 publicly
available control data sets of European
ancestry (ESP-NHLBI, 2012) and was
found to be significantly higher in
AGEP than expected by chance
(Po0.012, Fisher’s exact test). In the
Table 1. Clinical features of all AGEP cases
Females 56.25% (54/96)
Age of onset 60±18 years
Widespread pustules 68.8% (66/96)
Nonfollicular pustules 92.6% (87/96)
Mainly intertriginous pustules 22.9% (22/96)
Fever 74.7% (68/96)
Involvement of mouth 5.2% (5/96)
Involvement of lips 11.5% (11/96)
Abbreviation: AGEP, acute generalized exanthematous pustulosis.
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AGEP cohort as a whole, the mutations
had a frequency of 1.6% compared with
0.4% in control populations (ESP-
NHLBI, 2012), when including all
potentially damaging (Adzhubei et al.,
2010) missense variants described for
IL36RN (Supplementary Table S3
online). Next, we sought whether there
were any phenotypic and/or drug cul-
prits common to the putative IL36RN-
dependent AGEP subset (Table 2). Of
the four patients with IL36RN variations,
one had been validated as probable
AGEP and three as definite AGEP, even
though two had oral involvement,
which is an uncommon feature in
AGEP seen in only 3% of the IL36RN
wild-type cases (Po0.014, Fisher’s
exact test). The patient with the
homozygous IL36RN mutation had
involvement of the lips as well. The
typical sign of involvement of the inter-
triginous folds was found in the patient
with the homozygous IL36RN mutation,
but not in the heterozygous cases. The
IL36RN-mutated cases were associated
with exposure to amoxicillin in two
cases, clindamycin/rifampicin in one
case and piroxicam in the last patient.
Aminopenicillins are the top culprit
drugs in AGEP (Sidoroff et al., 2007),
making up 19% of all cases. Oxicam
nonsteroidal anti-inflammatory drugs
cause 3% of AGEP (Sidoroff et al.,
2007), and rifampicin/clindamycin are
less common triggers of AGEP (Sulewski
et al., 2008). A total of 83% of IL36RN
wild-type AGEP were associated
with antibiotics. The latency from first
Table 2. Clinical and genetic data for the four AGEP cases with IL36RN variants
Indi-
vidual Gender
Ethni-
city
Age at
onset
(years) Putative drug trigger
Previous
history
of drug-
induced
skin
reaction1
Latency
to onset
(days)
Final
AGEP
score
History
of
psoriasis
Systemic
features Pustules
Max.
leukocytes
IL36RN
mutation
AGEP-
01,
3350502
Female African 45 Amoxicillin given for
influenza-like illness. 3
months after AGEP, a
positive patch test to
amoxicillin was noted.
No recurrence during
observation period of
18 months
Yes,
Reaction type:
unknown
Drug:
antibiotic, class
unknown
2 Definite No Involvement
of mouth:
yes
Involvement
of lips: yes
Burning
pain: no
Pruritus: yes
Fever:
39.4 1C
Facial
edema: yes
Blisters: no
Widespread:
yes
Nonfollicular:
yes
Mainly
intertriginous:
yes
Maximal
involvement:
85%
BSA
15
109/l
Homozygous:
c.80T4C
(p.Leu27Pro)
AGEP-
02,
9130302
Female European 83 Amoxicillin given for an
unspecified infection
Yes
Reaction type:
uncomplicated
drug rash
Drug: penicillin
3 Definite No Involvement
of mouth:
yes
Involvement
of lips: no
Burning
pain: no
Pruritus: yes
Fever:
unknown
Facial
edema: yes
Blisters: yes
Widespread:
yes
Nonfollicular:
no
Mainly
intertriginous:
no
Maximal
involvement:
60%
BSA
35109/l Heterozygous:
c.338C4T
(p.Ser113Leu)
AGEP-
03,
9191174
Male European 83 Clindamycin/rifampicin
given for infection of
osteosynthesis
None known 13 Definite No Involvement
of mouth: no
Involvement
of lips: no
Burning
pain: no
Pruritus: no
Fever:
39.4 1C
Facial
edema: no
Blisters: no
Widespread:
yes
Nonfollicular:
yes
Mainly
intertriginous:
no
Maximal
involvement:
8%
BSA
22.2109/l Heterozygous:
c.338C4T
(p.Ser113Leu)
AGEP-
04,
9191166
Female Russian 55 Piroxicam given for
sinusitis
Yes
Reaction type:
unknown
Drug:
neomycin/
bacitracin
5 Probable No Involvement
of mouth: no
Involvement
of lips: no
Burning
pain: yes
Pruritus: yes
Fever:
unknown
Facial
edema: yes
Blisters: no
Widespread:
yes
Nonfollicular:
yes
Mainly
intertriginous:
no
Maximal
involvement:
53%
BSA
18.9109/l Heterozygous:
c.142C4T
(p.Arg48Trp)
Abbreviations: AGEP, acute generalized exanthematous pustulosis; RegiSCAR, International Registry of Severe Cutaneous Adverse Reaction.
1Data on past events incomplete and not part of the RegiSCAR study.
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drug intake to the beginning of the skin
eruption was median 4 (IQR25 3,
IQR75 7) days in patients with the
IL36RN variants and 4 (IQR25 1,
IQR75 7) days in wild-type AGEP. In
summary, in a large cohort study of
96 AGEP patients, 3 heterozygous and
1 homozygous potentially pathogenic
single-nucleotide substitutions in
IL36RN were identified. With perhaps
the exception of oral involvement, no
phenotypically distinct markers between
IL36RN-mutated and wild-type patients
were identified. These data suggest a
possible genetic basis for a small subset
of AGEP. However, as three of the
four mutations we have observed are
heterozygous and not homozygous,
other, as yet unknown, additional
mutations in associated inflammatory
cytokine family members or HLA
subtypes (Illing et al., 2012) jointly
acting with exogenous factors, such as
a drug, are likely to be required to elicit
disease. Our study did not include
pedigree information and genotypes
of the family members; thus, it remains
unclear whether the mutations were
de novo or inherited. As for any
disease lacking unequivocal diagnostic
criteria, misclassification of the four
cases with a mutation cannot be totally
excluded, but seems unlikely for the
following reasons: in three of the four
cases, diagnoses of AGEP had been
considered definite by the review
committee, all four had been exposed
to drugs known to induce AGEP, one
patient with AGEP to amoxicillin had
developed a drug rash to penicillin
previously, and hypersensitivity by
patch test to the putative culprit drug
was proven in an additional case. The
differential diagnosis of GPP to account
for the patients with IL36RN mutations
is unlikely, as GPP has a rather low
frequency of IL36RN mutations as well
(one in seven cases, Setta-Kaffetzi et al.,
accepted manuscript). Therefore, the
data set of 96 AGEPs would have to
contain at least misdiagnosed 28 GPP
cases to achieve 4 cases with IL36RN
mutations.
Thus, IL36RN variations can underlie
several different pustular skin eruptions,
which may also explain other pustular
phenotypes (Ameen et al., 2002) that
can occur spontaneously or during drug
treatment (Navarini et al., 2011). Only a
minority of GPP cases is affected by
mutations in IL36RN (Setta-Kaffetzi
et al., 2013); therefore, other stages of
the IL36 pathway might be affected at
some level in the remaining AGEP and
GPP, by mutation or other mechanisms.
Taken together, these data could provide
the basis to postulate that a small subset
of AGEP is due to IL-36Ra dysfunction.
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TO THE EDITOR
Multiple self-healing squamous
epithelioma (MSSE; OMIM132800), also
known as Ferguson-Smith disease, is a
rare, inherited skin cancer syndrome
characterized by multiple invasive
keratoacanthoma-like skin tumors that
regress spontaneously leaving pitted
scars (Ferguson-Smith, 1934; Goudie
et al., 1993). The majority of the
first-identified affected families have a
shared Scottish ancestry, but MSSE has
also been described in families of non-
Scottish origin (D’Alessandro et al.,
2007). Recently, the causative gene for
MSSE was identified as TGFBR1, encod-
ing a transmembrane serine/threonine
kinase receptor involved in TGF-b
signaling (Goudie et al., 2011). TGFBR1
mutations in MSSE are functionally null,
implying a tumor-suppressor action in
this disease, whereas missense mutations
in the same gene can lead to Marfan
syndrome–related disorders (Loeys et al.,
2005; Goudie et al., 2011). TGFBR1 had
previously been excluded as an MSSE
candidate because the gene lies outside
the original shared at-risk haplotype
(SRH) in the Scottish families (Bose
et al., 2006). However, using large-scale
sequencing technology, Goudie et al.
(2011) identified TGFBR1 germline
mutations in a total of 18 MSSE fami-
lies including 12 Scottish families. Of
nine Scottish families with the SRH,
seven families shared the same TGFBR1
mutation (p.G52R); importantly however,
two families had different causative
mutations (p.N45S and p.R414X). This
suggests that unidentified rare variants
associated with MSSE pathogenesis may
exist in the non-TGFBR1 SRH region
that has been conserved in nine
families. The fact that this relatively
large conserved haplotype had not
undergone recombination over many
generations in these nine affected
Scottish MSSE families suggested that
manifestation of the disease may
require both the causative TGFBR1
mutation and additional variants loca-
ted within the SRH region.
To search for these SRH variants, we
used the Agilent SureSelect Target
Enrichment system (Santa Clara, CA),
followed by sequencing on the Illumina
(San Diego, CA) GAII platform to
sequence all of the target genes between
the markers D9S197 and D9S1809 on
9q22-31 (D’Alessandro et al., 2007).
Thirteen families, including seven
Scottish families with the SRH, were
available (Supplementary Table S1
online). Family numbers hereafter corre-
spond to the study by Goudie et al.
(2011). We performed targeted
sequencing in five families with the
SRH and five families without the
SRH, along with six Centre d’Etude
du Polymorphisme Humain (CEPH)
controls. Coding regions of the 15
then-known genes were sequenced
previously (D’Alessandro et al., 2007);
however, based on NCBI36 (hg18),
there are now 29 known genes in the
targeted region (Supplementary Table S5
online), encompassing B2.2-Mb in
total, and this entire genomic region of
these genes was sequenced. After filter-
ing out common variants included in
dbSNP and shared with CEPH controls,
we identified nine noncoding variants
shared by all five families with the SRH.
None of the nine rare variants were
detected in MSSE families without the
SRH. These nine variants are located in
the intronic regions of five different
genes: FAM120A, PHF2, C9orf3,
FANCC, and PTCH1 (Table 1). SangerAccepted article preview online 28 January 2013; published online 7 March 2013
Abbreviations: CEPH, Centre d’Etude du Polymorphisme Humain; GA II, Genome Analyzer II; MSSE,
multiple self-healing squamous epithelioma; SCC, squamous cell carcinoma; SRH, shared at-risk
haplotype; TGFBR1, transforming growth factor beta receptor 1
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